Modeling Spinal Muscular Atrophy in Zebrafish: Current Advances and Future Perspectives
Open Access
- 6 February 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (4) , 1962
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by degeneration of lower motor neurons (LMNs), causing muscle weakness, atrophy, and paralysis. SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene and can be classified into four subgroups, depending on its severity. Even though the genetic component of SMA is well known, the precise mechanisms underlying its pathophysiology remain elusive. Thus far, there are three FDA-approved drugs for treating SMA. While these treatments have shown promising results, their costs are extremely high and unaffordable for most patients. Thus, more efforts are needed in order to identify novel therapeutic targets. In this context, zebrafish (Danio rerio) stands out as an ideal animal model for investigating neurodegenerative diseases like SMA. Its well-defined motor neuron circuits and straightforward neuromuscular structure offer distinct advantages. The zebrafish’s suitability arises from its low-cost genetic manipulation and optical transparency exhibited during larval stages, which facilitates in vivo microscopy. This review explores advancements in SMA research over the past two decades, beginning with the creation of the first zebrafish model. Our review focuses on the findings using different SMA zebrafish models generated to date, including potential therapeutic targets such as U snRNPs, Etv5b, PLS3, CORO1C, Pgrn, Cpg15, Uba1, Necdin, and Pgk1, among others. Lastly, we conclude our review by emphasizing the future perspectives in the field, namely exploiting zebrafish capacity for high-throughput screening. Zebrafish, with its unique attributes, proves to be an ideal model for studying motor neuron diseases and unraveling the complexity of neuromuscular defects.Keywords
Funding Information
- ANID-Millennium Science Initiative Program-ICN2021_044
- ANID/Fondecyt postdoctoral fellowship 3200061
This publication has 64 references indexed in Scilit:
- The role of survival motor neuron protein (SMN) in protein homeostasisCellular and Molecular Life Sciences, 2018
- Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired EndocytosisThe American Journal of Human Genetics, 2017
- The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA PhenotypeThe American Journal of Human Genetics, 2016
- Zebrafish as a genomics model for human neurological and polygenic disordersDevelopmental Neurobiology, 2011
- Seize the day: Newborn screening for SMAAmerican Journal of Medical Genetics Part A, 2010
- Newborn and carrier screening for spinal muscular atrophyAmerican Journal of Medical Genetics Part A, 2010
- Rare Missense and Synonymous Variants in UBE1 Are Associated with X-Linked Infantile Spinal Muscular AtrophyThe American Journal of Human Genetics, 2008
- The SMN binding protein gemin2 is not involved in motor axon outgrowthDevelopmental Neurobiology, 2007
- An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)Human Mutation, 2000
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995